Browsing Tag

EyePoint

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule…

Eli Pacheco Dec 17, 2022 0

WATERTOWN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to…

Health

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

Eli Pacheco Jul 11, 2022 0

- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas -…

Health

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

Eli Pacheco Nov 19, 2021 0

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to…

Health

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1…

Eli Pacheco Nov 6, 2021 0

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to…

Health

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial…

Eli Pacheco Oct 13, 2021 0

– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ® CALM registry study collecting real-world data on patients…